Neos Therapeutics (NEOS) Reaches New 12-Month Low at $4.75

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) hit a new 52-week low on Monday . The company traded as low as $4.75 and last traded at $4.85, with a volume of 13251 shares trading hands. The stock had previously closed at $5.05.

A number of analysts have weighed in on the company. ValuEngine upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a research report on Wednesday, August 8th. Finally, Wells Fargo & Co lowered their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, August 9th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.33.

The stock has a market cap of $148.37 million, a price-to-earnings ratio of -1.86 and a beta of -0.32. The company has a debt-to-equity ratio of -2.36, a current ratio of 1.07 and a quick ratio of 0.84.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%. The company had revenue of $11.36 million during the quarter, compared to the consensus estimate of $11.90 million. equities analysts expect that Neos Therapeutics Inc will post -1.69 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in NEOS. Allianz Asset Management GmbH bought a new stake in shares of Neos Therapeutics during the first quarter worth $161,000. Trexquant Investment LP bought a new stake in shares of Neos Therapeutics during the second quarter worth $131,000. New York State Common Retirement Fund grew its holdings in shares of Neos Therapeutics by 38.5% during the first quarter. New York State Common Retirement Fund now owns 24,100 shares of the company’s stock worth $200,000 after purchasing an additional 6,700 shares during the last quarter. OMERS ADMINISTRATION Corp grew its holdings in shares of Neos Therapeutics by 25.1% during the first quarter. OMERS ADMINISTRATION Corp now owns 46,360 shares of the company’s stock worth $385,000 after purchasing an additional 9,300 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Neos Therapeutics by 28.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock worth $352,000 after purchasing an additional 12,500 shares during the last quarter. Hedge funds and other institutional investors own 47.47% of the company’s stock.

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Article: Determine Your Level of Risk Tolerance

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply